BioLife Solutions (BLFS) Q2 2025: Cell Processing Revenue Up 28% as BPM Share Hits 70% of U.S. CGT Trials
BioLife Solutions delivered robust cell processing growth, deepening its leadership in late-stage cell therapy workflows. The company's BPM portfolio now powers over 70% of U.S. CGT trials, with commercial and clinical traction supporting a guidance raise despite ongoing macro uncertainty. Strategic investments in adjacencies and disciplined portfolio management reinforce BLFS’s positioning for durable growth and margin expansion into 2026.
Summary
- Late-Stage Dominance: BPM products now support over 70% of U.S. CGT trials, anchoring recurring demand.
- Margin Expansion Signals Leverage: Adjusted EBITDA margin rose 400 basis points as scale and mix improvements took hold.
- Portfolio Moves Accelerate Growth: Investments in Pluristics and Panthera expand future product and market reach.
Business Overview
BioLife Solutions develops and supplies biopreservation media, cell processing tools, and cold chain logistics products for the cell and gene therapy (CGT) industry. The company generates revenue primarily from its cell processing platform, led by biopreservation media (BPM), with additional contributions from EVO (logistics monitoring) and Thaw (automated thawing) segments. BLFS’s portfolio is deeply embedded in commercial therapies and clinical trial workflows, making it a critical supplier to advanced therapy manufacturers.
Performance Analysis
BioLife’s Q2 2025 results were driven by a 28% year-over-year surge in cell processing revenue, marking the seventh consecutive quarter of segment growth and reinforcing the company’s position as a default partner for late-stage and commercial CGT programs. BPM, which now represents 85% of cell processing revenue, continues to deliver recurring sales, with 80% of BPM revenue concentrated in the top 20 customers, providing strong forward visibility. Approximately 40% of BPM revenue is now tied to approved commercial therapies, underscoring resilience even as early-stage clinical demand remains softer.
Adjusted EBITDA margin expanded to 24%, up 400 basis points year-over-year, reflecting operating leverage from higher volume and a streamlined portfolio. While adjusted gross margin dipped to 65% (from 67% prior year) due to product mix and EVO fleet costs, gross profit dollars rose sharply on revenue strength. Operating expenses spiked on a $15.5 million non-cash IPR&D charge for the Panthera acquisition, but underlying adjusted OpEx was well controlled. Cash and securities ended at $100 million, supporting ongoing M&A and R&D initiatives.
- Recurring Revenue Strength: 80% of BPM sales are from top 20 customers, with 60% through direct sales and 40% via distribution, providing stable demand visibility.
- Commercial Therapy Embeddedness: 40% of BPM revenue comes from customers with approved therapies, helping buffer against early-stage funding volatility.
- Portfolio Optimization: CellSeal and HPL cross-sell efforts are gaining traction, with large pharma customers evaluating new integrations.
Management’s increased guidance reflects confidence in second-half demand, with little sign of seasonality or distributor weakness, even amid broader industry uncertainty.
Executive Commentary
"With over $100 million in cash and marketable securities at quarter end, we're operating from a position of strength, enabling us to invest in our strategic priorities. This includes advancing targeted growth initiatives, as evidenced by our recent investment in Pluristics, while continuing to drive market share in our core cell processing business."
Roderick DeGrief, Chairman and CEO
"Adjusted EBITDA for the second quarter of 2025 was $6.1 million, or 24% of revenue, compared with $3.9 million, or 20% of revenue, in the prior year. Adjusted EBITDA increased in the prior year primarily due to the $3.2 million improvement in gross margin driven by increased sales of biopreservation media."
Troy Wichterman, Chief Financial Officer
Strategic Positioning
1. BPM as the CGT Workflow Standard
BioLife’s BPM portfolio is now embedded in 16 approved therapies and over 250 U.S. CGT trials, capturing a 70%+ share in the clinical landscape and nearly 80% in Phase III trials. This deep integration with late-stage and commercial programs anchors recurring revenue and provides a moat against funding-driven volatility in earlier-stage research.
2. Cross-Selling and Product Adjacency Expansion
Management is intensifying cross-sell efforts, with large pharma customers trialing CellSeal, HPL, and the CT5 automated fill device. Early traction suggests potential for 2-3x revenue per dose when customers adopt multiple BLFS products. New reporting metrics are planned for Q3, signaling a more systematic approach to tracking cross-sell progress.
3. Disciplined M&A and Portfolio Optimization
The Panthera acquisition and Pluristics investment demonstrate a measured approach to expanding into adjacencies, such as biological assays, and reinforcing core biopreservation leadership. Management is evaluating long-term fit for EVO (logistics monitoring), while Thaw remains a steady contributor. M&A focus remains on products “between the walls” of cell manufacturing, with an eye toward market leadership and synergy with existing offerings.
4. Regulatory and Market Tailwinds
The FDA’s removal of REMS requirements for CGT therapies is expected to streamline clinical workflows, expand patient access, and ultimately increase therapy uptake. Management views this as a long-term tailwind for both BLFS and the broader CGT sector, supporting durable demand for core and adjacent products.
Key Considerations
BioLife’s Q2 marks a pivotal quarter of both execution and positioning, as the company leverages its commercial therapy embeddedness and recurring revenue base while selectively expanding its portfolio and capabilities.
Key Considerations:
- Visibility from Top Customers: 80% of BPM revenue is concentrated in 20 customers, enhancing demand forecasting and reducing revenue volatility.
- Cross-Sell Momentum: Early adoption of CellSeal and HPL by large pharma customers could drive significant revenue per dose expansion in future periods.
- Disciplined Capital Allocation: $100 million cash balance supports ongoing R&D, M&A, and product development without near-term liquidity risk.
- Product Mix and Margin Dynamics: Lower gross margin was offset by volume gains, but future mix shifts (e.g., new launches, EVO/Thaw performance) will be key to margin trajectory.
- Regulatory Shifts as Growth Catalysts: FDA’s relaxed monitoring requirements may accelerate commercial therapy adoption, benefiting BLFS’s embedded products.
Risks
Macro volatility, NIH funding pressures, and regulatory uncertainty remain latent risks, especially for early-stage clinical customers. Product mix headwinds and potential delays in customer adoption of new devices (such as the cryo case and CT5) could impact near-term growth and margin expansion. Continued discipline in M&A and capital allocation is essential, as integration missteps or overextension into adjacencies could dilute focus and returns.
Forward Outlook
For Q3 and Q4 2025, BioLife guided to:
- Full-year total revenue of $100 to $103 million, up from prior guidance of $95.5 to $99 million.
- Cell processing revenue of $91 to $93 million, reflecting 24% to 26% annual growth.
Management expects:
- Mid-60s adjusted gross margin for the full year, with further EBITDA margin expansion.
- No material revenue from Panthera in 2025, with new product launches expected in the back half of 2026.
Leadership expressed high confidence in second-half demand, citing strong order visibility from top customers and no signs of distributor or direct channel weakness. Cross-sell reporting will be introduced in Q3, and management continues to monitor regulatory and funding trends for potential impacts.
Takeaways
BioLife Solutions is solidifying its role as the backbone of commercial and late-stage CGT manufacturing workflows, with a recurring revenue base, expanding margin profile, and strategic moves into adjacent markets.
- Commercial Therapy Embeddedness: BPM’s presence in 16 approved therapies and 70% of U.S. trials anchors recurring demand and underpins guidance confidence.
- Cross-Sell and Portfolio Leverage: Early traction in cross-selling and adjacencies like Pluristics and Panthera could unlock new growth vectors and margin opportunities.
- Forward Watchpoint: Execution on new product launches, cross-sell conversion rates, and regulatory tailwinds will be critical to sustaining momentum into 2026.
Conclusion
BioLife Solutions delivered a strong Q2, underpinned by commercial therapy integration, margin expansion, and disciplined portfolio management. As the CGT sector matures, BLFS’s strategic positioning and operational execution set a high bar for recurring revenue quality and long-term growth potential.
Industry Read-Through
BioLife’s results reinforce the critical role of workflow standardization and supplier embeddedness in the CGT value chain. The company’s ability to deliver recurring, visible revenue despite sector funding volatility highlights the importance of late-stage and commercial focus for suppliers. Regulatory tailwinds, such as the FDA’s relaxed REMS requirements, signal accelerating therapy adoption, which should benefit other suppliers with entrenched workflows and cross-sell potential. Disciplined capital allocation and measured M&A are emerging as key differentiators, as sector leaders seek to expand capabilities without overextending balance sheets or diluting focus.